MAGMA fluctuated 52.5% in 24 hours: trading volume surged 250% and futures leveraged trading drove a rebound to $0.1497
Bitget Pulse2026/03/22 16:02Volatility Overview
In the past 24 hours, the price of MAGMA hit a low of $0.09813 and a high of $0.14968, with the current price at $0.12657. The overall amplitude reached 52.5%, and the price rebounded over 50% within the day. Trading volume surged significantly, with CoinGecko data showing a 24-hour trading volume of approximately $9.02 million and Bitget reporting a 250% spike in trading volume. In terms of capital flows, futures leveraged trading remained active, although there are no clear data on net inflows.
Brief Analysis of the Abnormal Move
- Futures leverage trading boost: According to Bitget, the MAGMA price rebounded from a low of $0.09575 to a high of $0.14968, with trading volume soaring by 250%, mainly driven by high leverage in futures trading.
- Speculative trading activity: Coinwink reported MAGMA as one of the top gainers in the past 24 hours, up 34.61%, with no official announcements or major on-chain whale moves detected.
Market Opinion and Outlook
Community sentiment leans bullish. Analysis from traders such as Finora AI indicates that as long as the price holds the $0.117–$0.131 support zone, a rebound towards the $0.138–$0.152 resistance zone can be expected. Some signals suggest a long target at $0.155–$0.200; however, caution is advised for potential fake breakouts at higher levels. If the price falls below $0.10, the trend could turn bearish.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million
RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.
Ledger CTO urges crypto holders to update iPhones after DarkSword exploit revealed
Crypto ICOs Left in Limbo After CLARITY Act Fails in Senate